114 related articles for article (PubMed ID: 9003519)
1. Identification of high-potency neuropeptide Y analogues through systematic lactamization.
Kirby DA; Britton KT; Aubert ML; Rivier JE
J Med Chem; 1997 Jan; 40(2):210-5. PubMed ID: 9003519
[TBL] [Abstract][Full Text] [Related]
2. Subtype selectivity and antagonistic profile of the nonpeptide Y1 receptor antagonist BIBP 3226.
Wieland HA; Willim KD; Entzeroth M; Wienen W; Rudolf K; Eberlein W; Engel W; Doods HN
J Pharmacol Exp Ther; 1995 Oct; 275(1):143-9. PubMed ID: 7562543
[TBL] [Abstract][Full Text] [Related]
3. Antagonistic properties of centrally truncated analogs of [D-Trp(32)]NPY.
Balasubramaniam A; Ujhelyi M; Borchers M; Huang Y; Zhai W; Zhou Y; Johnson M; Sheriff S; Fischer JE
J Med Chem; 1996 Mar; 39(5):1142-7. PubMed ID: 8676351
[TBL] [Abstract][Full Text] [Related]
4. Y1 and Y2 receptor selective neuropeptide Y analogues: evidence for a Y1 receptor subclass.
Kirby DA; Koerber SC; May JM; Hagaman C; Cullen MJ; Pelleymounter MA; Rivier JE
J Med Chem; 1995 Oct; 38(22):4579-86. PubMed ID: 7473586
[TBL] [Abstract][Full Text] [Related]
5. Defining structural requirements for neuropeptide Y receptors using truncated and conformationally restricted analogues.
Kirby DA; Koerber SC; Craig AG; Feinstein RD; Delmas L; Brown MR; Rivier JE
J Med Chem; 1993 Feb; 36(3):385-93. PubMed ID: 8426366
[TBL] [Abstract][Full Text] [Related]
6. Truncated, branched, and/or cyclic analogues of neuropeptide Y: importance of the pancreatic peptide fold in the design of specific Y2 receptor ligands.
Reymond MT; Delmas L; Koerber SC; Brown MR; Rivier JE
J Med Chem; 1992 Oct; 35(20):3653-9. PubMed ID: 1433176
[TBL] [Abstract][Full Text] [Related]
7. Fluorescent labelled analogues of neuropeptide Y for the characterization of cells expressing NPY receptor subtypes.
Ingenhoven N; Beck-Sickinger AG
J Recept Signal Transduct Res; 1997; 17(1-3):407-18. PubMed ID: 9029504
[TBL] [Abstract][Full Text] [Related]
8. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: evidence for subtype-differentiating effects on affinity and intrinsic efficacy.
Michel MC; Gaida W; Beck-Sickinger AG; Wieland HA; Doods H; Dürr H; Jung G; Schnorrenberg G
Mol Pharmacol; 1992 Oct; 42(4):642-8. PubMed ID: 1331755
[TBL] [Abstract][Full Text] [Related]
9. Vasoconstrictor effects of various neuropeptide Y analogues on the rat tail artery in the presence of phenylephrine.
Tschöpl M; Miller RC; Pelton J; Stoclet JC; Bucher B
Br J Pharmacol; 1993 Nov; 110(3):1098-104. PubMed ID: 8298798
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure, and antagonistic properties of des-Asn29[D-Trp28,32]NPY(27-36).
Balasubramaniam A; Zhai W; Tao Z; Huang Y; Fischer JE; Eden P; Taylor JE; Kar L; Samarasinghe SD; Johnson ME
Peptides; 1996; 17(7):1113-8. PubMed ID: 8959744
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of neuropeptide Y analogues with respect to Y1 and Y2 receptors.
Beck-Sickinger AG; Jung G
Biopolymers; 1995; 37(2):123-42. PubMed ID: 7893945
[TBL] [Abstract][Full Text] [Related]
12. Conformational and biological studies of neuropeptide Y analogs containing structural alterations.
Fournier A; Gagnon D; Quirion R; Cadieux A; Dumont Y; Pheng LH; St-Pierre S
Mol Pharmacol; 1994 Jan; 45(1):93-101. PubMed ID: 8302286
[TBL] [Abstract][Full Text] [Related]
13. Neuropeptide Y and the retinal pigment epithelium: receptor subtypes, signaling, and bioelectrical responses.
Ammar DA; Hughes BA; Thompson DA
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1870-8. PubMed ID: 9727410
[TBL] [Abstract][Full Text] [Related]
14. Binding of chimeric NPY/galanin peptides M32 and M242 to cloned neuropeptide Y receptor subtypes Y1, Y2, Y4, and Y5.
Berglund MM; Saar K; Lundell I; Langel U; Larhammar D
Neuropeptides; 2001; 35(3-4):148-53. PubMed ID: 11884204
[TBL] [Abstract][Full Text] [Related]
15. Identification of neuropeptide Y cleavage products in human blood to improve metabolic stability.
Khan IU; Reppich R; Beck-Sickinger AG
Biopolymers; 2007; 88(2):182-9. PubMed ID: 17206650
[TBL] [Abstract][Full Text] [Related]
16. Neuropeptide Y: Y1 and Y2 affinities of the complete series of analogues with single D-residue substitutions.
Kirby DA; Boublik JH; Rivier JE
J Med Chem; 1993 Nov; 36(24):3802-8. PubMed ID: 8254609
[TBL] [Abstract][Full Text] [Related]
17. A rational approach for the development of reduced-size analogues of neuropeptide Y with high affinity to the Y1 receptor.
Rist B; Wieland HA; Willim KD; Beck-Sickinger AG
J Pept Sci; 1995; 1(5):341-8. PubMed ID: 9223013
[TBL] [Abstract][Full Text] [Related]
18. Novel analogues of neuropeptide Y with a preference for the Y1-receptor.
Söll RM; Dinger MC; Lundell I; Larhammer D; Beck-Sickinger AG
Eur J Biochem; 2001 May; 268(10):2828-37. PubMed ID: 11358498
[TBL] [Abstract][Full Text] [Related]
19. Alpha-helical small molecular size analogues of neuropeptide Y: structure-activity relationships.
Jung G; Beck-Sickinger AG; Dürr H; Gaida W; Schnorrenberg G
Biopolymers; 1991 May; 31(6):613-9. PubMed ID: 1657233
[TBL] [Abstract][Full Text] [Related]
20. Molecular characterization of the human neuropeptide Y Y2-receptor.
Ingenhoven N; Eckard CP; Gehlert DR; Beck-Sickinger AG
Biochemistry; 1999 May; 38(21):6897-902. PubMed ID: 10346911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]